CD137 (Human) Activator/Inhibitor Screening Assay, HEK293 (CD137 & NF-κB)-based

This assay is used to screen for activators or inhibitors of CD137 signaling in a cellular context and characterize the biological activity of CD137 and its interactions with ligands. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

Customized to client's specific requirements

HEK293

Human

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant HEK293 cell line expressing a full length human CD137 (4-1BB) (NM_001561). The NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD137 ligand, NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. Which can be used in binding assays and functional assay.

HEK293 (CD137 & NF-κB)

Cancer

Oncology

In Vitro Activator/Inhibitor Screening Assay

Screen for activators or inhibitors of CD137 signaling in a cellular context and characterize the biological activity of CD137 and its interactions with ligands.

Creative Biolabs has developed several I-O function assay based on our stable cell Lines expressed the most popular immune checkpoints. CD137 (Human) Activator/Inhibitor Screening Assay, HEK293 (CD137 & NF-κB)-based is applied to screen for activators or inhibitors of CD137 signaling in a cellular context and characterize the biological activity of CD137 and its interactions with ligands. The assay will be customized according to the client's specific requirements. Please contact our scientists to discuss more details.

In Vitro Activator/Inhibitor Screening Assay; Activator/Inhibitor Screening Assay

NF-κB Reporter

Activator/Inhibitor Screening Assay

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant HEK293 cell line expressing a full length human CD137 (4-1BB) (NM_001561). The NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD137 ligand, NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. Which can be used in binding assays and functional assay.